As discussed earlier, the products under development for the treatment of life-threatening central nervous system (or CNS) disorders in Sage Therapeutics’ (SAGE) portfolio are either based on GABA or NMDA receptor systems.
The above chart shows the products under development for the GABA Receptor program.
GABA receptor-based products
Gamma-aminobutyric acid (or GABA) is an inhibiting neurotransmitter in the CNS. The products under development in the GABAA Receptor program, their uses, and the status of their development are as follows:
- SAGE-547 (brexanolone) is a drug under Phase III development for the treatment of postpartum depression. The company released the data from the STATUS trial, a phase III study evaluating Brexanolone as compared to a placebo, for the treatment of super refractory status epilepticus (or SRSE) on September 12, 2017, and announced that the study didn’t meet its primary endpoints.
- SAGE-217 is a drug under phase II development for the treatments of postpartum depression as well as other indications including major depressive disorder, essential tremor, and Parkinson’s disease.
- SAGE-689 is a drug under development in the pre-clinical phase for the treatment of patients with status epilepticus and other undisclosed uses.
- SAGE-105 is a drug under development in the pre-clinical phase, for the treatment of orphan epilepsies.
- SAGE-324 is a drug under development in the pre-clinical phase for GABA Hypofunction.
To divest company-specific risks, investors can consider ETFs like the First Trust NASDAQ Pharmaceuticals ETF (FTXH), which holds 5.3% of its total assets in Sage Therapeutics (SAGE). FTXH also holds 4.6% in Bristol-Myers Squibb (BMY), 4.1% in Eli Lilly (LLY), and 8.2% in Johnson & Johnson (JNJ).